LCD Reference Article Article

Response to Comments for MolDX: Biomarkers in Cardiovascular Risk Assessment

A54610

Expand All | Collapse All
Draft Article
Draft Articles are works in progress and not necessarily a reflection of the current billing and coding practices. Revisions to codes are carefully and thoroughly reviewed and are not intended to change the original intent of the LCD.

Document Note

Note History

Contractor Information

Article Information

General Information

Source Article ID
N/A
Article ID
A54610
Original ICD-9 Article ID
Not Applicable
Article Title
Response to Comments for MolDX: Biomarkers in Cardiovascular Risk Assessment
Article Type
Article
Original Effective Date
10/05/2015
Revision Effective Date
10/05/2015
Revision Ending Date
N/A
Retirement Date
N/A
AMA CPT / ADA CDT / AHA NUBC Copyright Statement

CPT codes, descriptions and other data only are copyright 2023 American Medical Association. All Rights Reserved. Applicable FARS/HHSARS apply.

Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.

Current Dental Terminology © 2023 American Dental Association. All rights reserved.

Copyright © 2023, the American Hospital Association, Chicago, Illinois. Reproduced with permission. No portion of the American Hospital Association (AHA) copyrighted materials contained within this publication may be copied without the express written consent of the AHA. AHA copyrighted materials including the UB‐04 codes and descriptions may not be removed, copied, or utilized within any software, product, service, solution or derivative work without the written consent of the AHA. If an entity wishes to utilize any AHA materials, please contact the AHA at 312‐893‐6816.

Making copies or utilizing the content of the UB‐04 Manual, including the codes and/or descriptions, for internal purposes, resale and/or to be used in any product or publication; creating any modified or derivative work of the UB‐04 Manual and/or codes and descriptions; and/or making any commercial use of UB‐04 Manual or any portion thereof, including the codes and/or descriptions, is only authorized with an express license from the American Hospital Association. The American Hospital Association (the "AHA") has not reviewed, and is not responsible for, the completeness or accuracy of any information contained in this material, nor was the AHA or any of its affiliates, involved in the preparation of this material, or the analysis of information provided in the material. The views and/or positions presented in the material do not necessarily represent the views of the AHA. CMS and its products and services are not endorsed by the AHA or any of its affiliates.

CMS National Coverage Policy

N/A

Article Guidance

Article Text
  1. Judicious Use of Biomarkers

    Comment: A commenter indicates there are occasions when it is necessary to accurately gauge a patient’s overall CV risk, and simple screening tests (lipids and CRP) are inadequate in capturing the majority of subjects at increased risk. Specifically:

    • LDL particles – (yields the same info as apoB) - may help to persuade for more intensive lipid lowering intervention beyond traditional goals;
    • Lipoprotein subclasses - LDL subclass - may help to persuade more intensive lipid lowering intervention beyond traditional goals;
    • Intermediate density lipoproteins - Limit to high TG subjects.
    • High density lipoprotein AI9LpAI and AI/AII – Occasionally apoAI or apoAII levels is helpful, particularly where HDL- c is markedly elevated and one wants to make sure there are actually increased levels of HDL particles
    • Lipoprotein(a) - typically limited to consult patient when assessing global risk,or when patient has a thrombotic event history without an eliciting risk factor. It is undeniable that LPa elevation predicts incident increased CVD event risk incremental to traditional RF, lipid profile levels and CRP.
    • Apolipoprotein B (Apo B), apo A-I and apo E – occasionally helpful apoB (when TG levels are markedly elevated making LDL-c calculation less accurate) and apoAI levels are helpful.
    • ApoE or apoE isoforms – not used in our institution
    • Lipoprotein-associated phospholipase A2 (Lp-PLA2) - to better gauge global CVD risks and to assess level of intensity of preventive efforts.
    • BNP - NT-proBNP presumably –
      • help identify those at increased risk for CVD incremental to traditional risk factors;
      • helpful in heart failure subjects or subjects with complaint of SOB;
      • to better gauge global CVD risks;
      • as with microalbumin, helps making decision of what type of BP medication to intensify sometimes.
    • Cystatin - elevated levels help identify increased risk for CKD development.
    • Thrombogenic/hematologic factors - Factor V Leiden, Protein C, anti-cardiolipin Antibodies, etc - very rarely used; maybe unexplained thrombotic event.
    • Interleukin-6 (IL-6), tissue necrosis factor- a (TNF- a) , plasminogen activator inhibitor-1 (PAI-1) and IL-6 promoter polymorphism – not used
    • Free fatty acids – rarely used
    • Visfatin, angiotensin-converting enzyme 1 (ACE2) and serum amyloid A – rarely used
    • Microalbumin – used
      • to gauge overall global CVD risks on initial consult;
      • to assess for early evidence of renal issues;
      • as withBNP, may help in BP medication to intensify
    • Myeloperoxidase (MPO) – occasionally at initial consult to gauge overall global CVD and thrombotic risks and to assess level of intensity of preventive efforts.
    • Homocysteine and methylenetetrahydrofolate reductase (MTHFR) mutation testing - rarely used
      • HCys is associated with incident CVD event risk and premature atherosclerotic heart disease;
      • HCys appropriate in patient with premature thrombotic event of unclear etiology;
      • In subjects with CKD, elevated HCys is very strong predictor of incident CVD risks and mortality risks; when elevated, intensification of global CVD risk reduction efforts
      • If dramatically elevated, triggers search for specific vitamin deficiencies.
    • Uric acid – some physicians under certain conditions use this to help identify those at increased risk for major adverse CV event risk incremental to traditional risk factors.


    The following are not used for CV risk assessment
    • Vitamin D
    • White blood cell count
    • Long-chain omega-3 fatty acids in red blood cell membrane
    • Gamma-glutamyltransferase (GGT)
    • Genomic profiling including CardiaRisk angiotensin gene
    • Leptin, ghrelin, adiponectin and adipokines, retinol binding protein 4 (RBP4) and resistin
    • Inflammatory markers including VCAM-1, P-selectin (PSEL) and E-selectin (ESEL)
    • Cardiovascular risk panels


    Response: The commenter and others confirm that, aside from lipids and CRP, biomarker testing is specific for a specific clinical condition/disease, or as in the latter group, not clinically indicated for CV risk assessment at all.

    General CV risk assessment panels, consisting of various combinations of biochemical, immunologic, hematologic, and molecular tests, constitutes patient screening, and are not a Medicare benefit. Medicare coverage for CV risk assessment is limited to the basic lipid panel under NCD (90.1). Under this policy, Medicare does cover the use of specific biomarkers (not as a broad risk panel) to characterize a given lipid abnormality or disease (e.g., diabetes), to determine a treatment plan or to assist with intensification of therapy.

    Comment: Another commenter writes “we share your view that biomarkers reviewed in this LCD lack compelling data for use in aiding CV risk assessment beyond conventional measures."

    Response: Generally agree.

  2. Coverage ApoB and LDL Particle Number

    Comment: Another commenter agrees with the LCD policy which views “non-traditional lipid markers” as well as other non-lipid biomarkers, as investigational for use in cardiovascular (CV) risk assessment. The commenter presents a thorough discussion for the role of LDL particle number and ApoB in high-risk populations to aid CV risk management.

    In brief, LDL particle number (NMR LDL-P), rather than LDL size or subclass, has been shown to be significantly associated with CV risk independent of traditional lipid and established risk factors. The American Association of Clinical Endocrinologists (AACE), the National Lipid Association (NLA), the American Diabetes Association (ADA) in conjunction with the American College of Cardiology (ACC), and the American Association of Clinical Chemistry (AACC) have developed consensus position statement on lipoprotein particle management in individuals at risk for CVD. Due to the prevalence of discordantly elevated LDL-P despite achieving low LDL-C and non-HDL-C values, each endorses use of LDL particle number to evaluate LDL response and aid decision making regarding potential adjustment of therapy. The 2013 AACE Comprehensive Diabetes Management Algorithm, as well as the 2015 joint AACE/American College of Endocrinology Clinical Practice Guidelines for Comprehensive Diabetes Mellitus Care, advocate specific LDL particle number goals for statin treated diabetic patients at high CV risk. The commenter presents a summary table of recommendations from expert societies advocating use of LDL particle number measure in CV risk management, and respectfully request coverage of LDL particle number and apoB for use in high-risk populations to aid CV risk management.

    Response: CGS and the MolDx contractor sincerely appreciates the comprehensive review of current data to support LDL particle number and apoB for high-risk populations. CGS and the MolDX contractor recognizes the role of LDL particle number, apoB and other individual biomarkers as clinically indicated in the management and treatment of CV disease. This policy is directed towards CV screening panels that exceed the basic lipid panel as specified in the NCD.


Response To Comments

Number Comment Response
1
N/A

Coding Information

Bill Type Codes

Code Description
N/A

Revenue Codes

Code Description
N/A

CPT/HCPCS Codes

Group 1

Group 1 Paragraph

N/A

Group 1 Codes

N/A

N/A

CPT/HCPCS Modifiers

Group 1

Group 1 Paragraph

N/A

Group 1 Codes

N/A

N/A

ICD-10-CM Codes that Support Medical Necessity

Group 1

Group 1 Paragraph

N/A

Group 1 Codes

N/A

N/A

ICD-10-CM Codes that DO NOT Support Medical Necessity

Group 1

Group 1 Paragraph

N/A

Group 1 Codes

N/A

N/A

ICD-10-PCS Codes

Group 1

Group 1 Paragraph

N/A

Group 1 Codes

N/A

N/A

Additional ICD-10 Information

N/A

Bill Type Codes

Contractors may specify Bill Types to help providers identify those Bill Types typically used to report this service. Absence of a Bill Type does not guarantee that the article does not apply to that Bill Type. Complete absence of all Bill Types indicates that coverage is not influenced by Bill Type and the article should be assumed to apply equally to all claims.

Code Description
N/A

Revenue Codes

Contractors may specify Revenue Codes to help providers identify those Revenue Codes typically used to report this service. In most instances Revenue Codes are purely advisory. Unless specified in the article, services reported under other Revenue Codes are equally subject to this coverage determination. Complete absence of all Revenue Codes indicates that coverage is not influenced by Revenue Code and the article should be assumed to apply equally to all Revenue Codes.

Code Description
N/A

Other Coding Information

Group 1

Group 1 Paragraph

N/A

Group 1 Codes

N/A

N/A

Coding Table Information

Excluded CPT/HCPCS Codes - Table Format
Code Descriptor Generic Name Descriptor Brand Name Exclusion Effective Date Exclusion End Date Reason for Exclusion
N/A N/A
N/A
Non-Excluded CPT/HCPCS Ended Codes - Table Format
Code Descriptor Generic Name Descriptor Brand Name Exclusion Effective Date Exclusion End Date Reason for Exclusion
N/A

Revision History Information

Revision History Date Revision History Number Revision History Explanation
10/05/2015 R1

Updated LCD Reference Article section.

N/A

Associated Documents

Medicare BPM Ch 15.50.2 SAD Determinations
Medicare BPM Ch 15.50.2
Related Local Coverage Documents
N/A
Related National Coverage Documents
N/A
SAD Process URL 1
N/A
SAD Process URL 2
N/A
Statutory Requirements URLs
N/A
Rules and Regulations URLs
N/A
CMS Manual Explanations URLs
N/A
Other URLs
N/A
Public Versions
Updated On Effective Dates Status
11/07/2023 10/05/2015 - N/A Currently in Effect You are here
08/14/2015 10/05/2015 - N/A Superseded View

Keywords

N/A